Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSK-V112
- Development stage
- Preclinical
- Lead developer
- WestVac Biopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
**WSK-V112** is a WestVac Biopharma recombinant bivalent prophylactic vaccine candidate designed to protect against both COVID-19 and influenza. It is produced using an insect-cell recombinant expression platform and is intended to generate antigen-specific immune responses to SARS-CoV-2 and influenza virus components. WestVac has reported protective effects in challenge experiments, investigator-initiated research at West China Hospital, and plans for Pre-IND submission. ([westvacpharma.com](https://www.westvacpharma.com/richtext/53))
- Other names
- Recombinant COVID-flu combination vaccineWSKV112WSKV-112WSKV 112
Beyond the preview
Go deeper on WSK-V112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WSK-V112.